Browse the evidence

Chronic insomnia is associated with a 24-hour hypersecretion of ACTH and cortisol (HPA axis activation) that retains a normal circadian rhythm, indicating a disorder of central nervous system hyperarousal rather than simple sleep loss.

Chronic insomnia is not just about not sleeping; it is a state of constant physiological stress (high cortisol/ACTH) that persists day and night. Treatment should focus on reducing this overall physiological and emotional hyperarousal, not just on improving sleep duration or using standard hypnotics. Consider therapies that target stress system down-regulation.

Cortical brain responses to sustained attention tasks decrease significantly with accrued sleep debt, whereas subcortical responses are primarily modulated by circadian rhythmicity and remain largely unaffected by sleep pressure.

If you are sleep-deprived, your brain's ability to sustain attention degrades specifically in cortical areas responsible for higher-order processing. This is not just 'feeling tired'; it is a measurable physiological change. To maintain performance, you must respect the circadian rhythm (melatonin timing) and avoid extending wakefulness into the biological night, as sleep debt will disproportionately impair cortical function.

Long-term DHEA replacement (50 mg/day) improves psychological well-being (specifically the 'role emotional' dimension of SF-36) in patients with primary adrenal insufficiency, but does not significantly improve fatigue, cognitive function, or sexual function.

For people with Addison's disease, DHEA might help with emotional well-being and feeling like you can handle daily roles, but don't expect it to fix fatigue or memory problems. It's a targeted treatment for a specific hormonal lack.

Obesity is a risk factor for several cancers, including colon, pancreas, kidney, prostate, breast, and endometrium, potentially through mechanisms involving chronic inflammation, insulin resistance, and adipocytokine production.

Keeping a healthy weight can help reduce the risk of several types of cancer. This is achieved through a combination of healthy eating, regular physical activity, and maintaining a healthy body composition.

Leptin and estrogen signaling modulate the skeleton's sensitivity to mechanical loading, with leptin deficiency requiring higher body weight to achieve equivalent bone mass.

Hormonal health, particularly leptin and estrogen levels, influences how effectively your bones respond to body weight. Hormonal imbalances can decouple the protective effect of weight on bones, meaning weight management alone may not be sufficient for bone health in all individuals.

Continuous positive airway pressure (CPAP) therapy reverses oxidative stress and improves endothelial function in patients with obstructive sleep apnea (OSA).

If you have OSA, using CPAP therapy nightly is the most effective way to protect your heart and blood vessels by reversing the oxidative stress caused by breathing pauses. While it can be uncomfortable at first, it is superior to antioxidant supplements for treating the root cause.

Obstructive sleep apnea (OSA) causes oxidative stress through intermittent hypoxia, leading to endothelial dysfunction and increased cardiovascular disease risk.

Untreated OSA creates a cycle of oxygen deprivation that damages blood vessels through oxidative stress, increasing the risk of hypertension and heart disease. Treating OSA is crucial for long-term cardiovascular health.

Slow-wave sleep (SWS) episodes are temporally associated with a significant decrease in plasma cortisol levels, suggesting an inhibitory relationship or synchronized regulation between deep sleep and adrenocortical quiescence.

Prioritize slow-wave sleep (deep sleep) to help regulate cortisol levels. This study shows that deep sleep phases are strongly linked to drops in cortisol. If you are struggling with high stress or cortisol-related issues, focusing on sleep hygiene to maximize deep sleep duration may be as effective as other stress-management techniques.

Myostatin induces reactive oxygen species (ROS) production in skeletal muscle cells via a feed-forward loop involving NF-κB activation, TNF-α upregulation, and NADPH oxidase (Nox1) expression, leading to muscle wasting.

This research highlights a biological mechanism where the protein myostatin triggers oxidative stress and inflammation in muscle, leading to muscle loss. While this is a natural process in aging or disease, it suggests that targeting the inflammatory pathway (NF-κB/TNF-α) might help preserve muscle mass, rather than just focusing on exercise or nutrition alone.

Musclin, an exercise-stimulated myokine, enhances physical endurance and aerobic capacity by potentiating ANP signaling to increase cGMP, thereby promoting PGC1-α-dependent mitochondrial biogenesis in skeletal muscle.

This research identifies musclin as a key messenger released by muscles during exercise that helps build mitochondria, the energy powerhouses of cells. While musclin itself is not currently available as a therapeutic, the findings reinforce that physical activity triggers specific hormonal responses that improve endurance. To boost this pathway, engage in regular aerobic exercise, which naturally stimulates musclin production and subsequent mitochondrial biogenesis.

Calcium supplementation (≥1,000 mg/day) increases the risk of cardiovascular events, including myocardial infarction and coronary heart disease, particularly in men and postmenopausal women.

If you are taking calcium supplements, especially doses over 1,000 mg per day, be aware that this may increase your risk of heart disease, particularly if you are a man or postmenopausal woman. Prioritize dietary calcium sources, which do not appear to carry this risk, and consult your doctor about your specific cardiovascular risk profile before continuing high-dose supplementation.

Peripheral hormones (leptin, insulin, ghrelin, PYY, GLP-1, CCK) regulate appetite and energy balance by acting on the hypothalamus and brainstem, with resistance to these hormones contributing to obesity.

Understand that hormones like leptin and insulin play a crucial role in hunger and satiety. In obesity, these hormones may become resistant, making it harder to regulate appetite. Medical treatments targeting these hormones (like GLP-1 agonists) may be effective.

Short-term (5-week) exercise interventions, whether HIIT or MVCT, significantly reduce serum testosterone and estradiol levels in obese young women, but do not significantly alter blood lipid profiles (TC, LDL, TG, HDL).

If you are an obese young woman, 5 weeks of exercise (HIIT or continuous) will likely lower your sex hormones (testosterone and estradiol), which may help with hormonal balance. However, do not expect your cholesterol or triglycerides to improve in just 5 weeks; you likely need to exercise for longer or burn more total calories per week to see changes in blood lipids.

Use of specific antiretroviral medications, particularly lopinavir/ritonavir and didanosine (ddI), significantly increases the risk of developing metabolic syndrome in HIV-infected adults, independent of general inflammation markers.

If you are HIV-positive, your medication choice matters for your metabolic health. Drugs like Kaletra (lopinavir/ritonavir) and didanosine are linked to a higher risk of metabolic syndrome. Discuss lipid management and body composition with your provider, but do not stop your medication without medical advice, as uncontrolled viral load is also a major risk factor.

Increasing viral load (specifically a >= 0.5-log increase) and higher trunk-to-limb fat ratio are significant independent predictors of metabolic syndrome incidence in HIV-infected adults, regardless of BMI adjustments.

Your metabolic health is closely tied to how well your HIV is controlled and where your body stores fat. Keeping your viral load low and monitoring your body composition (specifically trunk fat) are critical. If you notice changes in your body shape or your viral load rises, talk to your doctor about adjusting your treatment or managing your lipids.

Skeletal muscle disuse (immobilization, bed rest, or unloading) causes rapid muscle atrophy primarily through a significant reduction in muscle protein synthesis (MPS), while muscle protein breakdown (MPB) remains largely unchanged or is not the primary driver.

If you are immobilized or unable to exercise (e.g., cast, bed rest), your muscles will stop building protein rapidly, leading to atrophy. You cannot simply 'wait it out' without loss. Focus on countermeasures like high-quality protein intake and any permitted mechanical loading (like electrical stimulation or isometric exercises) to mitigate the drop in muscle protein synthesis.

Obesity causes male infertility through multiple mechanisms including hormonal disruption (low testosterone/high estrogen), increased scrotal temperature, and oxidative stress from adipokines.

If you are obese and struggling with fertility, weight loss is a primary medical treatment. It can restore hormonal balance and improve semen quality. Consult a doctor for a weight management plan.

In obese individuals, systemic inflammation drives a shift in tryptophan metabolism toward the kynurenine pathway (increased KYN/TRP ratio) and away from serotonin and microbial indole production, correlating with higher inflammatory markers.

This research highlights that obesity is linked to specific changes in how your body processes tryptophan, shifting it away from serotonin production and toward inflammatory pathways. While this paper does not offer a direct intervention, it suggests that managing systemic inflammation and gut health (via diet and lifestyle) may be key to normalizing these metabolic pathways.

Long-term glucocorticoid treatment causes insulin resistance, glucose intolerance, and abnormal weight gain by suppressing osteoblast function and osteocalcin synthesis; disrupting this skeletal signaling pathway prevents these metabolic adverse effects.

This research suggests that the metabolic side effects of long-term glucocorticoid use (like weight gain and insulin resistance) are partly driven by the suppression of bone-derived hormones (osteocalcin). While this is a mouse study, it implies that maintaining bone health or osteocalcin levels might mitigate metabolic risks in patients on steroids, though direct human interventions are not yet established.

Short-term ADT (3-6 months) induces insulin resistance and hyperinsulinemia while maintaining normal fasting glucose levels, whereas long-term ADT (12+ months) leads to frank hyperglycemia and diabetes.

Monitor your blood sugar closely. In the first few months of treatment, your body may compensate for insulin resistance by producing more insulin, keeping blood sugar normal. However, after a year, this compensation often fails, leading to diabetes. Regular glucose tolerance tests are recommended for those on long-term therapy.

ADT causes unfavorable body composition changes, specifically increasing fat mass (particularly visceral/subcutaneous) and decreasing lean body mass, which correlates with rising insulin levels.

Expect to gain fat and lose muscle on ADT. This is not just cosmetic; the fat gain, especially around the abdomen, drives insulin resistance. Focus on resistance training and protein intake to mitigate muscle loss, and cardiovascular exercise to manage fat gain.

Growth hormone does not accelerate fat loss in obese subjects during caloric restriction, despite increasing free fatty acid (FFA) mobilization.

Do not use Growth Hormone expecting it to help you lose more fat. It increases the amount of fat in your blood temporarily, but it does not help you lose more body fat than dieting alone. It is not an effective fat-loss strategy.

Growth hormone causes fluid retention (edema) and weight gain in the first week of treatment, which resolves after treatment stops, resulting in no net difference in total weight loss compared to placebo.

Expect to gain 1-2 pounds in the first week of Growth Hormone therapy due to water retention. This is normal and temporary. Do not stop treatment because of this initial weight gain; it will resolve after you stop the injections.

SIRT1 levels in the brain decline with age, leading to cognitive impairment and metabolic dysfunction, while maintaining or increasing SIRT1 activity preserves synaptic plasticity and memory.

Maintaining brain health involves supporting SIRT1 activity, which declines with age. This supports the importance of lifestyle factors (like exercise and caloric restriction) that are known to upregulate SIRT1, potentially preserving memory and synaptic plasticity.